Before prescribing HADLIMA, please read the accompanying Prescribing Information, including the Boxed Warning about serious infections and malignancies. The Medication Guide and Instructions for ...

About HADLIMA™ (adalimumab-bwwd) Injection 40 mg/0.4 mL and 40 mg/0.8 mL HADLIMA is a tumor necrosis factor (TNF) blocker indicated for: ...

Hadlima first received FDA approval in 2019 as a 50 mg/mL prefilled syringe or prefilled autoinjector. A higher-concentration 100 mg/mL formulation was later approved in August 2022.

The U.S. Department of Veterans Affairs will replace Humira with the biosimilar Hadlima on its national formulary, according to a press release from Organon, which markets biosimilar. Hadlima ...

These interchangeability designations follow the interchangeability designation received for the Hadlima low-concentration (40 mg/0.8 ml) prefilled syringe and single-dose vial in June 2024.

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection Business Wire May 27, 2025 ...

Before prescribing HADLIMA, please read the accompanying Prescribing Information, including the Boxed Warning about serious infections and malignancies. The Medication Guide and Instructions for ...

About HADLIMA™ (adalimumab-bwwd) Injection 40 mg/0.4 mL and 40 mg/0.8 mL HADLIMA is a tumor necrosis factor (TNF) blocker indicated for: ...

About HADLIMA™ (adalimumab-bwwd) Injection 40 mg/0.4 mL and 40 mg/0.8 mL HADLIMA is a tumor necrosis factor (TNF) blocker indicated for: ...